Valuation: Panacos Pharmaceuticals, Inc.

Market Cap 7.32M 6.4M 5.91M 5.51M 10.39M 692M 10.58M 70.91M 27.53M 341M 27.49M 26.87M 1.19B P/E 2006
-5.32x
P/E 2007 -1.12x
Enterprise Value -25.27M -22.12M -20.42M -19.04M -35.88M -2.39B -36.52M -245M -95.07M -1.18B -94.93M -92.81M -4.11B EV / Sales 2006
504x
EV / Sales 2007 53.9x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
Manager TitleAgeSince
Chief Executive Officer 69 -
Director of Finance/CFO 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+10.00%-72.50% - - 53
+3.31%+1.93%+69.29%+129.27% 55.78B
-1.32%+16.55%+89.14%+101.41% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
+4.45%+8.43%+37.08%-29.19% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+5.51%+22.37%+171.85%+333.54% 14.8B
+1.83%+4.58%+77.42%+132.45% 12.16B
-2.37%+6.47%+157.84%+161.16% 11.85B
Average +2.22%+6.15%+68.82%+156.10% 25.17B
Weighted average by Cap. +1.20%+5.02%+65.91%+142.28%

Financials

2006 2007
Net sales 284K 249K 229K 214K 403K 26.85M 411K 2.75M 1.07M 13.25M 1.07M 1.04M 46.16M 180K 158K 145K 136K 256K 17.02M 260K 1.74M 677K 8.4M 676K 661K 29.26M
Net income -38.11M -33.36M -30.79M -28.72M -54.12M -3.6B -55.09M -369M -143M -1.78B -143M -140M -6.19B -37.46M -32.79M -30.27M -28.23M -53.2M -3.54B -54.15M -363M -141M -1.75B -141M -138M -6.09B
Net Debt -60.4M -52.87M -48.81M -45.53M -85.78M -5.71B -87.32M -585M -227M -2.82B -227M -222M -9.82B -32.58M -28.52M -26.33M -24.56M -46.27M -3.08B -47.1M -316M -123M -1.52B -122M -120M -5.3B
Logo Panacos Pharmaceuticals, Inc.
Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Employees
-